KK
VRDN icon

KLP Kapitalforvaltning’s Viridian Therapeutics VRDN Stock Holding History

KLP Kapitalforvaltning’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$321K Buy
17,500
+3,600
+26% +$58K ﹤0.01% 1699
2026
Q1 		$272K Hold
13,900
– – ﹤0.01% 1701
2025
Q4 		$433K Buy
13,900
+2,500
+22% +$68.6K ﹤0.01% 1484
2025
Q3 		$246K Hold
11,400
– – ﹤0.01% 1737
2025
Q2 		$159K Hold
11,400
– – ﹤0.01% 1869
2025
Q1 		$154K Hold
11,400
– – ﹤0.01% 1863
2024
Q4 		$219K Buy
+11,400
New +$248K ﹤0.01% 1781

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

KLP Kapitalforvaltning's VRDN Position: Q2 2026 in Review

KLP Kapitalforvaltning increased its Viridian Therapeutics (VRDN) stake by 26% in Q2 2026, buying an estimated $58K and bringing the position to 17,500 shares worth $321K. The position accounts for ﹤0.01% of the portfolio, ranked #1699.

KLP Kapitalforvaltning first reported a position in VRDN in Q4 2024 and has held it in 7 quarters since. The position peaked at $433K in Q4 2025. 215 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • KLP Kapitalforvaltning held 17,500 shares of Viridian Therapeutics worth $321K as of Q2 2026.
  • KLP Kapitalforvaltning bought 3,600 Viridian Therapeutics shares in Q2 2026, an estimated $58K.
  • Viridian Therapeutics made up ﹤0.01% of KLP Kapitalforvaltning's portfolio in Q2 2026, its #1699 holding.
  • KLP Kapitalforvaltning first reported a position in Viridian Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • KLP Kapitalforvaltning's Viridian Therapeutics position peaked at $433K in Q4 2025.
  • 215 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on KLP Kapitalforvaltning's 13F filing for Q2 2026, filed 12 Aug 2026.